Združene države Amerike - angleščina - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, lipitor can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, lipitor is indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for corona

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, lipitor can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, lipitor is indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for corona

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bryant ranch prepack - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, lipitor can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, lipitor is indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for corona

Irska - angleščina - HPRA (Health Products Regulatory Authority)

primecrown 2010 ltd - atorvastatin - film coated tablet - 80 milligram - hmg coa reductase inhibitors

Združene države Amerike - angleščina - NLM (National Library of Medicine)

physicians total care, inc - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin calcium 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, lipitor can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, lipitor is indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for co

Irska - angleščina - HPRA (Health Products Regulatory Authority)

ltt pharma limited - atorvastatin - film-coated tablet - 80 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irska - angleščina - HPRA (Health Products Regulatory Authority)

ltt pharma limited - atorvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin;   - film coated tablet - 10 mg - active: atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - lipitor is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium 21.7mg equivalent to 20 mg atorvastatin;   - film coated tablet - 20 mg - active: atorvastatin calcium 21.7mg equivalent to 20 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - lipitor is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium 43.4mg equivalent to 40 mg atorvastatin;   - film coated tablet - 40 mg - active: atorvastatin calcium 43.4mg equivalent to 40 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - lipitor is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.